Syndax Pharmaceuticals Inc (SNDX) Form 8-K — Jun 10, 2026
$SNDXForm 8-KItems 1.01, 2.03, 3.02, 9.01Filed Jun 10, 2026, 8:00 AM ET0001193125-26-266027Original filing
Syndax Pharmaceuticals Inc. (SNDX) closed a private placement of $250 million in aggregate principal amount of 2.25% Convertible Senior Notes due 2031 on June 10, 2026. The company received approximately $243 million in net proceeds after deducting placement agent fees and expenses. The notes are convertible into common stock at an initial rate of 54.5256 shares per $1,000 principal amount, allowing for the issuance of up to 13,631,400 shares upon conversion.
Key figures
- Debt Amount
- 250000000
- Interest Rate
- 2.25
- Maturity Date
- 2031-06-15
- Gross Proceeds
- 250000000
- Net Proceeds
- 243000000
- Initial Conversion Rate
- 54.5256
- Max Shares Issuable Upon Conversion
- 13631400
Price after filing
1 day: +1.9%7 days: +8.3%30 days: +41.3%
Close on the filing date to close N calendar days later (from $17.58). Historical, not a forecast.
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.